• PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND-A DISCRETE EVENT SIMULATION MODELLING

    Oct 1, 2009, 00:00

  • PDB61 DIABETES REGIMEN UTILIZATION IN A LARGE MANAGED CARE SETTING; A COMPARISON WITH ADA/EASD CONSENSUS STATEMENT GUIDELINES

    Oct 1, 2009, 00:00

  • MO6 MODELLING COST EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS- A NOVEL APPROACH

    Oct 1, 2009, 00:00

  • PIN56 COST-EFFECTIVENESS OF ATAZANAVIR/R VS. LOPINAVIR/R IN TREATMENT NAIVE HIV PATIENTS IN SPAIN

    Oct 1, 2009, 00:00

  • PCV16 COMPARATIVE EFFICACY OF LOSARTAN AND IRBESARTAN IN HYPERTENSIVE PATIENTS AT SARABURI HOSPITAL, THAILAND 2007

    Oct 1, 2009, 00:00

  • PUK5 THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    Oct 1, 2009, 00:00

  • PCN151 CROSS-REGIONAL FLOWS OF CANCER PATIENTS IN GREECE- URBANIZATION OF CANCER TREATMENT

    Oct 1, 2009, 00:00

  • PIN61 COST-UTILITY ANALYSIS OF ROTAVIRUS VACCINE (ROTARIX) IN JAPAN

    Oct 1, 2009, 00:00

  • PDB52 PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN- RESULTS FROM THE LIVE-COM STUDY

    Oct 1, 2009, 00:00

  • PCV28 BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION- A POPULATION ANALYSIS OF NET CLINICAL BENEFIT

    Oct 1, 2009, 00:00

  • PSY24 A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN- GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS

    Oct 1, 2009, 00:00

  • PMH5 USING TREEMAPS TO ASSESS PHYSICAL COMORBIDITY RISK IN PATIENTS WITH BIPOLAR DISORDER

    Oct 1, 2009, 00:00

  • PIH14 THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND

    Oct 1, 2009, 00:00

  • PCV24 A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CLINICAL TRIALS REVIEWING ANTI-ARRHYTHMIC DRUGS FOR THE TREATMENT OF ATRIAL FIBRILLATION

    Oct 1, 2009, 00:00

  • PCV44 HEART FAILURE IN OLDER PEOPLE- A STUDY OF FACTORS THAT LEAD TO HOSPITALISATION

    Oct 1, 2009, 00:00

  • PCV162 PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM-THE SIMVASTATIN CASE

    Oct 1, 2009, 00:00

  • PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HE ...

    Oct 1, 2009, 00:00

  • PCN7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM

    Oct 1, 2009, 00:00

  • PHP31 A POLICY FRAMEWORK FOR FUNDING DRUGS FOR RARE DISEASES

    Oct 1, 2009, 00:00

  • PRS14 MEDICAL AND PRODUCTIVITY COSTS ATTRIBUTABLE TO OBESITY IN WORKING ADULTS WITH ASTHMA IN THE U.S.

    Oct 1, 2009, 00:00

  • PMS19 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PCV152 ASSESSING THE IMPACT OF A COMMUNITY PHARMACY BASED MTM PROGRAM ON OUTCOMES FOR EMPLOYEES WITH HYPERTENSION

    Oct 1, 2009, 00:00

  • PCN154 ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003-2007

    Oct 1, 2009, 00:00

  • PCV141 UPPER GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH CARDIOVASCULAR RISK TAKING LOW-DOSE ACETYLSALICYLIC ACID- AN OBSERVATIONAL STUDY

    Oct 1, 2009, 00:00

  • PHP63 CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH TECHNOLOGIES IN SPAIN

    Oct 1, 2009, 00:00

  • PHP90 PATIENT-HEALTH CARE PROVIDER COMMUNICATION- IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE

    Oct 1, 2009, 00:00

  • PIN45 COST-EFFECTIVENESS OF A COCOONING IMMUNIZATION STRATEGY AGAINST PERTUSSIS FOR THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PHP27 AVALIANICA- O CASO DE BELO HORIZONTE (MG)

    Oct 1, 2009, 00:00

  • PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY

    Oct 1, 2009, 00:00

  • PMS27 DIRECT AND INDIRECT COSTS OF RHEUMATOID ARTHRITIS MANAGEMENT IN POLAND

    Oct 1, 2009, 00:00

  • PCN38 TREATMENT PATTERNS OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE TO ANTHRACYCLINE AND TAXANE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCN106 EXPLORING THE COST-EFFECTIVENESS OF A SMOKING-CESSATION PROGRAM ENHANCED WITH INDIVIDUAL GENETIC FEEDBACK ON LUNG CANCER RISK

    Oct 1, 2009, 00:00

  • PCN65 INPATIENT COST AND REIMBURSEMENT FOR PATIENTS WITH PROGRESSIVE MALIGNANT THORACIC NEOPLASM IN GERMANY

    Oct 1, 2009, 00:00

  • PCN71 COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE

    Oct 1, 2009, 00:00

  • PHP91 IMPLANTABLE LOOP RECORDERS IN UNEXPLAINED TRANSIENT LOSS OF CONSCIOUSNESS (T-LOC) DIAGNOSTICS- A COST-SAVING OPPORTUNITY FOR THE UK NATIONAL HEALTH SERVICE (NHS)

    Oct 1, 2009, 00:00

  • PMS94 MANAGEMENT AND DIAGNOSIS OF OSTEOPOROTIC VERTEBRAL FRACTURES ACCORDING TO PRIMARY CARE PHYSICIANS

    Oct 1, 2009, 00:00

  • PMS13 BUDGETARY IMPACT OF A NEW URATE-LOWERING THERAPY (ULT) FOR THE TREATMENT OF GOUT IN A US HEALTH PLAN FORMULARY

    Oct 1, 2009, 00:00

  • PCV111 A PATIENTS VIEW OF THE COST-EFFECTIVENESS OF USING LOWDOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK

    Oct 1, 2009, 00:00

  • PSY3 MODELO DE COSTO BENEFICIO ENTRE BUPRENORFINA TRANSDERMICA, MORFINA PARENTERAL Y OXICODONA ORAL, EN EL TRATAMIENTO DE PACIENTES CON DOLOR CRONICO MODERADO A SEVERO EN UN SERVICIO DE SALUD DE ATENCION DOMICILIARIA

    Oct 1, 2009, 00:00

  • PCV83 RELATIONSHIP BETWEEN THE COST AND HOSPITAL QUALITY

    Oct 1, 2009, 00:00

  • PDB36 COST SAVINGS IN TYPE 2 DIABETES WITH INSULIN GLARGINE COMPARED TO INSULIN DETEMIR IN A BASAL-BOLUS TREATMENT CONCEPT IN GERMANY

    Oct 1, 2009, 00:00

  • PSY42 BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY- AN EXAMINATION OF QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PCV35 PRASUGREL AND CLOPIDOGREL PERSISTENCE AND DISCONTINUATION AMONG LOWER BLEEDING RISK PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROMES

    Oct 1, 2009, 00:00

  • PMH15 INITIAL HIGH-DOSE PRESCRIPTION OF DULOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER- DEMOGRAPHIC AND CLINICAL PREDICTORS

    Oct 1, 2009, 00:00

  • PDB33 A COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE-I DIABETES PATIENTS IN ITALY

    Oct 1, 2009, 00:00

  • PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

    Oct 1, 2009, 00:00

  • PRS7 IMPACT OF COUGH AND/OR SPUTUM SYMPTOMS ON THE BURDEN OF COPD IN EUROPE AND THE USA- A CROSS-SECTIONAL, OBSERVATIONAL STUDY

    Oct 1, 2009, 00:00

  • PDB80 MEASURING GLYCOSYLATED HAEMOGLOBIN LEVELS IN PATIENTS WITH DIABETES- IMPACT OF LOWER QOF TARGETS ON ACHIEVEMENT OF CLINICAL INDICATORS AND QOF POINTS

    Oct 1, 2009, 00:00

  • PND38 COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GILLES DE LA TOURETTES SYNDROME

    Oct 1, 2009, 00:00

  • PMC58 EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PCN127 DYNAMIC CONTRAST-ENHANCED ULTRASOUND WITH QUANTIFICATION TO ASSESS TARGETED TREATMENT EFFICACY- RESULTS OF A MULTI-CENTRIC PROSPECTIVE COST STUDY

    Oct 1, 2009, 00:00

  • PND40 PATIENT REPORTED OUTCOMES IN THE EARLY STAGES OF MULTIPLE SCLEROSIS- THE BEGIN STUDY

    Oct 1, 2009, 00:00

  • PR5 TRANSLATION AND LINGUISTIC VALIDATION- EVIDENCE TO SUGGEST THAT AN IN-COUNTRY REVIEW IS NECESSARY

    Oct 1, 2009, 00:00

  • PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

    Oct 1, 2009, 00:00

  • PCV149 ASSESSMENT OF QUALITY OF LIFE AMONG PATIENTS WITH HYPERTENSION AND DIABETES TYPE 2

    Oct 1, 2009, 00:00

  • PND37 RESPONSIVENESS AND CLINICAL IMPORTANT DIFFERENCES OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS- RESULTS OF A LARGE MULTINATIONAL OBSERVATION STUDY

    Oct 1, 2009, 00:00

  • PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MXICO

    Oct 1, 2009, 00:00

  • PP1 A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING

    Oct 1, 2009, 00:00

  • CS13 CLINICAL EFFECTIVENESS AND COST UTILITY OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAVE HIV-1 INFECTED PATIENTS IN MEXICO

    Oct 1, 2009, 00:00

  • PIN40 COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO

    Oct 1, 2009, 00:00

  • PCN78 COST-EFFECTIVENESS ASSESSMENT OF ZOLEDRONIC ACID (ZOL) RELATIVE TO PLACEBO (PBO) IN THE TREATMENT OF LUNG CANCER PATIENTS WITH SKELETAL METASTASES IN FIVE EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PMC15 A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE

    Oct 1, 2009, 00:00

  • PMS76 PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DMI)- A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT

    Oct 1, 2009, 00:00

  • PCV32 A CROSS-SECTIONAL ASSESSMENT OF PREVALENCE OF LIPID DISORDERS AMONG FRENCH PATIENTS IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PMS26 HEALTH CARE RESOURCES AND COSTS OF FIBROMYALGIA- A REVIEW OF THE EVIDENCE

    Oct 1, 2009, 00:00

  • PCN136 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS- TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS

    Oct 1, 2009, 00:00

  • PIN31 COST-EFFECTIVENESS ANALYSIS OF TELBIVUDINE VS LAMIVUDINE IN TREATING THE PATIENTS WITH HBEAG-POSITIVE AND -NEGATIVE CHRONIC HEPATITIS B IN CHINA

    Oct 1, 2009, 00:00

  • PIN6 OUTCOME AND RESOURCES USE OF SEVERE BURN INJURY PATIENTS WITH NOSOCOMIAL BLOODSTREAM INFECTION- RESULTS OF A MATCHED COHORT STUDY

    Oct 1, 2009, 00:00

  • PMH4 A SYSTEMATIC REVIEW OF THE REAL-WORLD STUDY EVIDENCE COMPARING THE SAFETY AND TOLERABILITY OF DONEPEZIL, RIVASTIGMINE AND GALANTAMINE FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE

    Oct 1, 2009, 00:00

  • PHP38 HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY

    Oct 1, 2009, 00:00

  • PDB8 ANTIDIABETIC DRUG UTILIZATION IN A UNIVERSITY HEALTH CARE SETTING

    Oct 1, 2009, 00:00

  • PIN64 A PROBABILISTIC COST-EFFECTIVENESS MODEL FOR PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN

    Oct 1, 2009, 00:00

  • PSS9 COSTS OF PATIENTS WITH OCCUPATIONAL SEVERE CHRONIC HAND ECZEMA REFRACTORY TO TOPICAL CORTICOSTEROIDS FOR EMPLOYERS MUTUAL INSURANCE COMPANIES IN SPAIN

    Oct 1, 2009, 00:00

  • PCV22 CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES

    Oct 1, 2009, 00:00

  • PMH57 NON-ADHERENCE TO ORAL ANTIPSYCHOTICS IN SCHIZOPHRENIA- RELAPSE AND UTILIZATION OF HEALTH CARE RESOURCES IN A 6-MONTH FOLLOW-UP PERIOD

    Oct 1, 2009, 00:00

  • PSS25 COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS

    Oct 1, 2009, 00:00

  • PCN3 EXPERIENCIA CLAS CELULAS (CPNPC)

    Oct 1, 2009, 00:00

  • PCV23 CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON RIESGO CARDIOVASCULAR

    Oct 1, 2009, 00:00

  • PHP51 ASSESSMENT OF PRESCRIPTION DRUG KNOWLEDGE AND THE IMPACT OF COUNSELING ON IT IN PATIENTS VISITING A PUBLIC TEACHING HOSPITAL IN NORTH INDIA

    Oct 1, 2009, 00:00

  • PCV85 COST CONSEQUENCES OF REDUCED CVD RISK THROUGH IMPROVED SBP CONTROL- A COMPARATIVE ANALYSIS OF VALSARTAN VERSUS LOSARTAN

    Oct 1, 2009, 00:00

  • PCN2 DOSE DELAY AMONGST CANCER PATIENTS UNDERGOING CHEMOTHERAPY

    Oct 1, 2009, 00:00

  • PSS7 THE APPLICATION OF DISCRETE EVENT SIMULATION TO QUANTITATIVE RISK BENEFIT ANALYSIS

    Oct 1, 2009, 00:00

  • CN5 COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY

    Oct 1, 2009, 00:00

  • PIN3 PREDICTORS OF EFFECTIVENESS WITH LOPINAVIR/RITONAVIR (LPV/R) SINGLE AGENT THERAPY (SAT) TO IMPROVE CLINICAL OUTCOMES IN HIGH RISK HIV+ PATIENTS IN AN URBAN CLINIC

    Oct 1, 2009, 00:00

  • PCV84 AN ASSESSMENT OF THE COST OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION USING MELODY VERSUS SURGICAL VALVE REPLACEMENT IN PATIENTS WITH RIGHT VENTRICULAR OUTFLOW TRACT DYSFUNCTION

    Oct 1, 2009, 00:00

  • PMS51 COST-MINIMIZATION ANALYSIS OF IV BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PCN152 NEW JAPANESE PREFECTURAL GOVERNMENT CANCER CONTROL PROGRAMS- A SYSTEMATIC REVIEW AND AN INTERNATIONAL COMPARISON

    Oct 1, 2009, 00:00

  • PSY15 A COMPARATIVE OUTCOMES ANALYSIS OF DIFFERENT BARIATRIC SURGERIES

    Oct 1, 2009, 00:00

  • PIN70 PERCEPTION AND ACCEPTANCE OF INTRADERMAL INFLUENZA VACCINE MEASURED BY THE VACCINEES PERCEPTION OF INJECTION (VAPI) QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PHP12 SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET

    Oct 1, 2009, 00:00

  • PCV150 WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN PATIENTS WITH METABOLIC SYNDROME- A COMPARISON OF THE UNITED STATES, EUROPE, AND JAPAN

    Oct 1, 2009, 00:00

  • PHP70 HTA INSITE- ANALYSIS OF AN ON-LINE DATABASE OF ALL NICE SUBMISSIONS AND DECISIONS

    Oct 1, 2009, 00:00

  • PHP35 COMPARATIVE ASSESSMENT OF POSITIVE REIMBURSEMENT LISTS AND HTA EFFECTIVENESS IN ADRIATIC REGION

    Oct 1, 2009, 00:00

  • PMS65 IMPACT OF MINIMAL ACCESS SPINAL TECHNOLOGIES (MAST) ON HOSPITALIZATION COST- A FRENCH EXPERIENCE

    Oct 1, 2009, 00:00

  • PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRE ...

    Oct 1, 2009, 00:00

  • PCN130 HEALTH UTILITIES OF CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN DFCI 95-01 RANDOMIZED CLINICAL TRIAL

    Oct 1, 2009, 00:00

  • PDB37 COST-MINIMIZATION ANALYSIS COMPARING BASAL ANALOGUE INSULINS IN HUNGARY

    Oct 1, 2009, 00:00

  • MO8 MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES

    Oct 1, 2009, 00:00

  • PCN54 A DESCRIPTIVE ANALYSIS OF SUBJECTS WITH METASTATIC GASTRIC CANCER (MGC)

    Oct 1, 2009, 00:00

  • PCV39 RETROSPECTIVE CLAIM DATABASE ANALYSIS OF THE IMPACT OF THE ASCOT-TYPE PROFILE ON ALL-CAUSES MORTALITY AND CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS WITHOUT KNOWN CORONARY HEART DISEASE IN A MEDITERRANEAN POPULATION IN SPAIN

    Oct 1, 2009, 00:00

  • PSY45 DEVELOPMENT OF A QUESTIONNAIRE TO EVALUATE TREATMENT SATISFACTION OF PATIENTS WITH SEVERE CROHNS DISEASE- QUALITATIVE STEPS

    Oct 1, 2009, 00:00

  • PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT- SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Oct 1, 2009, 00:00

  • PCV116 COST-EFFECTIVENESS OF BIVALIRUDIN VERSUS HEPARIN PLUS GLYCOPROTEIN IIB/IIIA INHIBITOR IN THE TREATMENT OF ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION-A HORIZONS TRIAL ANALYSIS USING UK VALUATIONS

    Oct 1, 2009, 00:00

  • PCV10 A MARGINAL STRUCTURAL MODEL TO COMPARE THE EFFECTIVENESS OF INDIVIDUAL ANGIOTENSIN RECEPTOR BLOCKERS IN VETERANS WITH CHRONIC HEART FAILURE

    Oct 1, 2009, 00:00

  • PSY28 IRON DEFICIENCY IN SWEDEN-TREATMENT OPTIONS, COSTEFFECTIVENESS AND REIMBURSEMENT

    Oct 1, 2009, 00:00

  • PMC4 LARGELY IGNORED- THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR

    Oct 1, 2009, 00:00

  • PCN25 REVISITICOS

    Oct 1, 2009, 00:00

  • PCV24 ANLISIS DEL CONSUMO DE AGENTES HIPOLIPEMIANTES EN COLOMBIA DEL 2002 AL 2006

    Oct 1, 2009, 00:00

  • PIH13 THE IMPACT OF FAMILY PHYSICIAN PROGRAM ON HEALTH INDICATORS IN IRAN (2003-2007)

    Oct 1, 2009, 00:00

  • PCV90 PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY RESUSCITATION- AN ANALYSIS OF OUTCOME, QUALITY OF LIFE AND COST-EFFECTIVENESS

    Oct 1, 2009, 00:00

  • PCV118 ECONOMIC EVALUATION OF INHALED ILOPROST IN PRIMARY PULMONARY HYPERTENSION IN THE UK

    Oct 1, 2009, 00:00

  • PRS3 A MICROSIMULATION ECONOMIC MODEL TO EVALUATE THE DISEASE BURDEN ASSOCIATED WITH SMOKING IN ARGENTINA

    Oct 1, 2009, 00:00

  • PCV62 PULMONARY ARTERIAL HYPERTENSION (PAH) COST OF ILLNESS IN THE U.S. PRIVATELY-INSURED POPULATION

    Oct 1, 2009, 00:00

  • PMS1 BUDGET IMPACT ANALYSIS OF ZOLEDRONIC ACID IN POST MENOPAUSAL OSTEOPOROSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • EE2 DEAR POLICYMAKER- HAVE YOU MADE UP YOUR MIND?

    Oct 1, 2009, 00:00

  • PMH38 COST-EFFECTIVENESS OF PREGABALIN VERSUS ISRS/ISRN IN BENZODIAZEPINE-REFRACTORY OUT-PATIENTS WITH GENERALIZED ANXIETY DISORDER- AN ECONOMIC EVALUATION UNDER MEDICAL USUAL PRACTICE IN MENTAL HEALTH CENTERS

    Oct 1, 2009, 00:00

  • PIH37 ASSESSMENT OF THE QUALITY OF LIFE IN WOMEN WITH VENOUS DISEASE

    Oct 1, 2009, 00:00

  • PCV136 HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS

    Oct 1, 2009, 00:00

  • PSY11 DEFI (DETERMINATION OF EPIDEMIOLOGY OF FIBROMYALGIA) A FRENCH PREVALENCE STUDY OF FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PMH47 ASSOCIATION BETWEEN ANTIPSYCHOTIC TREATMENT AND CLINICAL AND ECONOMIC OUTCOMES IN SCHIZOPHRENIA AND BIPOLAR DISORDER

    Oct 1, 2009, 00:00

  • PRS28 ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT ASTHMA- A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES AND RELATED COST/UTILITY

    Oct 1, 2009, 00:00

  • PG112 RESOURCE UTILIZATION AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C (CHC) IN THAILAND- A HEAVY BUT MANAGEABLE ECONOMIC BURDEN

    Oct 1, 2009, 00:00

  • PHP94 ASSESSMENT OF SHORT AND LONG TERM INGUINAL HERNIA RECURRENCE CASES AFTER HEAVY WEIGHT MESH DEVICE UTILIZATION UNDER PUBLIC HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL. WILL THE NEW TECHNOLOGIES IMPROVE THE SURGICAL OUTCOMES?

    Oct 1, 2009, 00:00

  • PMS67 THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AND DIRECT CARE COSTS AMONG PATIENTS WITH FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PHP15 EVALUATION OF SEVERITY SCORING INDICES IN ACUTE ORGANOPHOSPHORUS POISONED PATIENTS IN A TERTIARY CARE HOSPITAL

    Oct 1, 2009, 00:00

  • PCV169 ACETYLSALICYLIC ACID(ASA) MONOTHERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE- AN ASSESSMENT OF THE MEDICAL BENEFIT USING THE IQWIG METHODOLOGICAL APPROACH

    Oct 1, 2009, 00:00

  • PMC34 SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    Oct 1, 2009, 00:00

  • PIH15 AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA

    Oct 1, 2009, 00:00

  • PMS70 USE OF QUALITATIVE RESEARCH TO ELICIT PATIENT-REPORTED OUTCOME APPROACHES IN OSTEOPOROSIS

    Oct 1, 2009, 00:00

  • PCN15 ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO

    Oct 1, 2009, 00:00

  • PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES- THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL

    Oct 1, 2009, 00:00

  • PND47 ASSESSING CANADIANSS DISEASE MEDICATIONS

    Oct 1, 2009, 00:00

  • PCV41 ESTIMATION OF PERSONS ELIGIBLE FOR ICD/CRT THERAPY IN WESTERN EUROPE UNDER THE CURRENT ESC GUIDELINES- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2009, 00:00

  • PIN51 COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO

    Oct 1, 2009, 00:00

  • PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS- A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK

    Oct 1, 2009, 00:00

  • PMH1 COMPLIANCE WITH ANTIPSYCHOTIC DRUGS AND HOSPITALIZATION- A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF PEOPLE WITH SCHIZOPHRENIA

    Oct 1, 2009, 00:00

  • PSY27 COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC

    Oct 1, 2009, 00:00

  • PCV22 EFFECTS OF TADALAFIL ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    Oct 1, 2009, 00:00

  • PGI3 COST-EFFECTIVENESS OF PEG-IFN ALPHA 2A OR 2B PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C IN MEXICO

    Oct 1, 2009, 00:00

  • PSY20 COSTS AND COST DRIVERS OF IMMUNE TOLERANCE INDUCTION (ITI) IN PATIENTS WITH HEMOPHILIA AND INHIBITORS

    Oct 1, 2009, 00:00

  • PCN11 COST ANALYSIS OF THE TREATMENT OF ADVANCED METASTATIC STS IN THE IMSS- ESTIMATING MEDICAL COST WITH CENSORED DATA

    Oct 1, 2009, 00:00

  • PIN81 MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS

    Oct 1, 2009, 00:00

  • PDB71 GLYCAEMIC AND CHOLESTEROL CONTROL OF TYPE 2 DIABETIC PATIENTS ATTENDING SPECIALIST OUTPATIENT CLINICS IN SINGAPORE

    Oct 1, 2009, 00:00

  • PRS35 OPINION OF ASTHMA PATIENTS TREATED ACCORDING TO GINA 2006 GUIDELINES-THE EPAGGELIA STUDY

    Oct 1, 2009, 00:00

  • UT3 HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE ROTAVIRUS INFECTIONS

    Oct 1, 2009, 00:00

  • PCV67 A COST-OF-ILLNESS ANALYSIS OF ATRIAL FIBRILLATION IN SWEDEN

    Oct 1, 2009, 00:00

  • PMC41 CONTROLLING FOR UNOBSERVABLE BIAS- IS THE CURE WORSE THAN THE DISEASE?

    Oct 1, 2009, 00:00

  • PCV59 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN

    Oct 1, 2009, 00:00

  • PND3 EFFICACY AND TOLERABILITY OF NATALIZUMAB IN RELAPSING MULTIPLE SCLEROSIS; A META-ANALYSIS

    Oct 1, 2009, 00:00

  • PIN17 THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES- A STUDY IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PUK12 COST-EFFECTIVENESS OF ACE INHIBITOR THERAPY TO PREVENT DIALYSIS IN NON-DIABETIC NEPHROPATHY-INFLUENCE OF THE ACE INSERTION / DELETION POLYMORPHISM

    Oct 1, 2009, 00:00

  • PRS25 CAN THE FRENCH GATEKEEPING SYSTEM BE COST-EFFECTIVE FOR PATIENTS WITH CHRONIC RESPIRATORY DISORDER?

    Oct 1, 2009, 00:00

  • PDB51 USING FACTOR ANALYSIS TO CONFIRM THE VALIDITY OF DIABETES HEALTH PROFILE-I, DIABETES AND LIFE STYLE FOR TURKISH DIABETIC PATIENTS

    Oct 1, 2009, 00:00

  • DE2 INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PMH61 PATIENTS PREFERENCES IN ADULTS WITH ADHD-A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2009, 00:00

  • PMC63 IS EXTENDING OF TIME TRADE-OFF EXPERIMENT TO 23 STATES PER RESPONDENT RATIONALIZED? ANALYSIS OF DATA FROM POLISH VALUATION STUDY

    Oct 1, 2009, 00:00

  • PCV107 ECONOMIC EVALUATION OF EZETIMIBE COMBINED WITH SIMVASTATIN FOR TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA

    Oct 1, 2009, 00:00

  • PMS21 MIXED TREATMENT COMPARISONS- AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Oct 1, 2009, 00:00

  • PMH51 TRENDS IN RATES OF PEDIATRIC BIPOLAR DISORDER-RELATED HOSPITALIZATIONS AND RELATED RESOURCE USE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PIH25 TIME AND SUPPLIES FOR WOUND MANAGEMENT DURING AND AFTER BREAST REDUCTION SURGERY IN GERMANY AND THE NETHERLANDS- PRINEO* VS STANDARD OF CARE

    Oct 1, 2009, 00:00

  • PCN99 COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN PATIENTS WITH SUPERFICIAL BASAL CELL CARCINOMA AND CONTRAINDICATION TO SURGICAL INTERVENTION/CRYOTHERAPY

    Oct 1, 2009, 00:00

  • PCV61 COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS- RESULTS OF HF-ACTION TRIAL

    Oct 1, 2009, 00:00

  • PHP12 PHARMACOECONOMIC CONTRIBUTION OF LATIN AMERICA TO ISPOR CONFERENCES

    Oct 1, 2009, 00:00

  • PRS1 TOBACCO AND INCOME LEVEL- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2009, 00:00

  • PMH70 DAILY AVERAGE CONSUMPTION AND AVERAGE DAILY COSTS OF DULOXETINE, VENLAFAXINE-XR, AND PREGABALIN AMONG US COMMERCIALLY INSURED PATIENTS

    Oct 1, 2009, 00:00

  • PMS22 A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN

    Oct 1, 2009, 00:00

  • PND19 COST-EFFECTIVENESS OF SUGAMMADEX IN THE MANAGEMENT OF PATIENTS WITH UNANTICIPATED DIFFICULT INTUBATION AND PATIENTS NEEDING RAPID SEQUENCE INTUBATION

    Oct 1, 2009, 00:00

  • PND42 INTERPRETING SCORES ON THE MULTIPLE SCLEROSIS-SPECIFIC PRIMUS AND U-FIS OUTCOME MEASURES

    Oct 1, 2009, 00:00

  • PCV88 THE COST EFFECTIVENESS OF AMBRISENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN IRELAND

    Oct 1, 2009, 00:00

  • PCASE1 AMPLIANICAS-FMUSP- DESAFIOS E OPORTUNIDADES

    Oct 1, 2009, 00:00

  • PIN5 CARGA FINANCIERA POR HEPATITIS A EN MXICO

    Oct 1, 2009, 00:00

  • PMC10 HOW TO MAKE USE OF AVAILABLE SURVIVAL EVIDENCE IN AN INDIRECT COMPARISON

    Oct 1, 2009, 00:00

  • PCV98 COST-EFFECTIVENESS OF ORGANISED INPATIENT CARE FOR STROKE

    Oct 1, 2009, 00:00

  • PMH12 COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS - ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT

    Oct 1, 2009, 00:00

  • PMH4 COSTS AND CONSEQUENCES FOR METABOLIC SYNDROME, DIABETES AND CORONARY HEART DISEASE (CHD) RISK AMONG SCHIZOPHRENIA PATIENTS TREATED WITH ARIPIPRAZOLE VERSUS OLANZAPINE IN BRAZIL

    Oct 1, 2009, 00:00

  • PMH62 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE- VALIDATION OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER

    Oct 1, 2009, 00:00

  • PCV13 EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND SIMVASTATIN IN THE REDUCTION OF CARDIOVASCULAR EVENTS- AN INDIRECT COMPARISON META-ANALYSIS

    Oct 1, 2009, 00:00

  • PCV71 PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME IN SPAIN- AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL

    Oct 1, 2009, 00:00

  • PSY23 COST OF FIRST LINE TREATMENT OF NON-HODGKINS LYMPHOMA AT PRIVATE HOSPITAL EN MEXICO

    Oct 1, 2009, 00:00

  • PMS24 THE SOCIAL AND ECONOMIC COSTS OF SPINA BIFIDA IN ITALY- A COST OF ILLNESS STUDY

    Oct 1, 2009, 00:00

  • PMC76 PATIENT REGISTRIES-A LITERATURE REVIEW OF RECENTLY REPORTED REGISTRY BASED STUDIES

    Oct 1, 2009, 00:00

  • PCV158 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM- USAGE IN CROATIA DURING A SEVEN-YEAR PERIOD

    Oct 1, 2009, 00:00

  • PND31 HEALTH UTILITY SCORES ASSOCIATED WITH A HYPOTHETICAL MODERATE ALZHEIMERS DISEASE HEALTH STATE- A CANADIAN SURVEY OF THE GENERAL PUBLIC

    Oct 1, 2009, 00:00

  • PCV33 ADHERENCE AND PERSISTENCE WITH STATIN THERAPY- PHARMACOUTILIZATION ANALYSIS FROM ADMINISTRATIVE DATABASES OF 5 ITALIAN LOCAL HEALTH UNITS (LHU)

    Oct 1, 2009, 00:00

  • PSY34 COST-UTILITY OF BARIATRIC SURGERY IN THE TREATMENT FOR MORBID OBESITY IN FINLAND

    Oct 1, 2009, 00:00

  • PGI5 WHAT ARE THE COSTS FOR NON-COMPLIANCE WITH GUIDELINES FOR TREATMENT OF CHRONIC HEPATITIS C?

    Oct 1, 2009, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY

    Oct 1, 2009, 00:00

  • PMS81 HAQ-BASED UTILITIES USING EUROQOL, BRAZIERS SHORT FORM-6D, AND VAS-QOL HAVE DIFFERENT VALUES AND MAY NOT ALL DISCRIMINATE ACROSS DISEASE SEVERITY AMONG A PORTUGUESE COHORT OF RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2009, 00:00

  • PCV23 WHAT IS THE EFFECTIVENESS OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES WHEN USED AS MONOTHERAPY IN THE REAL-WORLD?

    Oct 1, 2009, 00:00

  • PMC36 CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE

    Oct 1, 2009, 00:00

  • PSY54 COST-EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY FOR GAUCHERS DISEASE IN THE URAL ADMINISTRATION DISTRICT OF RUSSIA FEDERATION

    Oct 1, 2009, 00:00

  • PND34 REVIEW OF PATIENT-REPORTED OUTCOME MEASURES FOR DAYTIME FUNCTIONING

    Oct 1, 2009, 00:00

  • VA3 GLOBAL MEASLES ERADICATION- COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020-2049

    Oct 1, 2009, 00:00

  • PMH60 A CONCEPTUAL MODEL OF RELEVANT TO PATIENTS DIAGNOSED WITH SCHIZOPHRENIA

    Oct 1, 2009, 00:00

  • PHP8 GASTOS COM MEDICAMENTOS E CARATERDE DE FORTALEZA EM 2007

    Oct 1, 2009, 00:00

  • CS16 COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO

    Oct 1, 2009, 00:00

  • PCN18 ECONOMIC EVALUATION OF SUNITINIB VS. IMATINIB IN SECOND LINE FOR GASTROINTESTINAL TUMOR (GIST) IN BRAZIL

    Oct 1, 2009, 00:00

  • PDB26 THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION

    Oct 1, 2009, 00:00

  • PG14 SYSTEMATIC REVIEW- THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHNS DISEASE

    Oct 1, 2009, 00:00

  • PMH2 SCHIZOPHRENIA MODELING- FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE

    Oct 1, 2009, 00:00

  • CS8 THE ECONOMIC BURDEN OF GAUCHER AND FABRYS DISEASE IN COLOMBIA. IMPLICATIONS FOR NATIONAL HEALTH INSURANCE

    Oct 1, 2009, 00:00

  • PMS62 INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS

    Oct 1, 2009, 00:00

  • PND35 FACTORS DRIVING PATIENT SELECTION OF PRIMARY MEDICATION FOR MULTIPLE SCLEROSIS

    Oct 1, 2009, 00:00

  • PHP76 DESIGN AND TESTING OF AN INDICATOR (FINANCIAL BIAS INDICATOR (FBI)) THAT ESTIMATES THE INFLUENCE OF FUNDING IN THE RESULTS (FINANCING BIAS (FB)) OF ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES (EEHT)

    Oct 1, 2009, 00:00

  • PND17 THE COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PARKINSONS DISEASE PATIENTS

    Oct 1, 2009, 00:00

  • PHP78 THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)

    Oct 1, 2009, 00:00

  • MO9 HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS

    Oct 1, 2009, 00:00

  • PHP46 WTP FOR A QALY- THE INDIVIDUAL PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIH36 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN POSTMENOPAUSAL WOMEN ENROLLED IN POSSIBLE EU

    Oct 1, 2009, 00:00

  • PCV48 A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTICOAGULATION STRATEGIES IN PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2009, 00:00

  • PHP85 RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA

    Oct 1, 2009, 00:00

  • PCN91 LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER

    Oct 1, 2009, 00:00

  • PCN26 RELATIVE IMPACT OF SCREENING AND THERAPEUTIC PROGRESS ON THE REDUCTION OF BREAST CANCER SPECIFIC MORTALITY IN FRANCE- A SIMULATION MODEL OVER THE PERIOD 1994-2005

    Oct 1, 2009, 00:00

  • PCV94 THE COST-EFFECTIVENESS OF TITRATION TO GOAL WITH BRAND ROSUVASTATIN COMPARED TO GENERIC SIMVASTATIN IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL- PRIMARY AND SECONDARY PREVENTION IN THE BELGIAN HEALTH CARE SETTING

    Oct 1, 2009, 00:00

  • PRS24 THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND

    Oct 1, 2009, 00:00

  • PMH28 INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Oct 1, 2009, 00:00

  • CASE1 DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES- EXPERIENCE FROM HUNGARY

    Oct 1, 2009, 00:00

  • PDB4 COST OF TYPE 2 DIABETES COMPLICATIONS IN MEXICO

    Oct 1, 2009, 00:00

  • PCV69 THE COST-OF-ILLNESS OF ATRIAL FIBRILLATION- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PCN121 COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND

    Oct 1, 2009, 00:00

  • PCV133 INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH CHRONIC HEART DISEASES

    Oct 1, 2009, 00:00

  • PND6 ESTIMATION OF PER-MEMBER-PER-YEAR COSTS FOR MANAGING FALLS OR FRACTURES AMONG HYPNOTIC USERS IN A MANAGED CARE PLAN

    Oct 1, 2009, 00:00

  • PMH19 MEASUREMENT OF CHRONIC STRESS BETWEEN PEOPLE WORKING IN PROFIT-ORIENTED ENVIRONMENT

    Oct 1, 2009, 00:00

  • PCN27 COST MINIMIZATION ANALYSIS OF TEGAFUR-URACIL ASSOCIATED TO LEUCOVORIN (UFT/LV) VERSUS CAPECITABINE ALONE FOR METASTATIC COLORECTAL CANCER UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIN65 IMPACT OF ETRAVIRINE (ETR) ON HOSPITALISATIONS AND HOSPITAL-RELATED COSTS CALCULATED BY GERMAN-DRGS- 48-WEEK FINDINGS FROM POOLED DUET TRIALS

    Oct 1, 2009, 00:00

  • PRS36 XOLAIR QUALITY OF LIFE RESULTS AS MEASURED IN A BELGIAN OBSERVATIONAL STUDY IN PATIENTS WITH SEVERE ALLERGIC ASTHMA

    Oct 1, 2009, 00:00

  • PSY6 USTEKINUMAB IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN OVERALL HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PSORIASIS PATIENTS

    Oct 1, 2009, 00:00

  • DE1 MARKET CONCENTRATION AND ITS CROSS-LINKAGE WITH THE CONSUMPTION OF ACE INHIBITORS AND ARBS

    Oct 1, 2009, 00:00

  • PSY30 COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA

    Oct 1, 2009, 00:00

  • PSY26 ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA

    Oct 1, 2009, 00:00

  • PCASE4 AVALIAO CONTROLADA POR REGRAS DE ELEGIBILIDADE

    Oct 1, 2009, 00:00

  • PSY55 IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE- ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES

    Oct 1, 2009, 00:00

  • PMH10 EFFECTIVENESS AND COST-EFFECTIVENESS OF LIFESTYLE INTERVENTIONS IN PERSONS WITH SEVERE MENTAL DISORDERS. A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PCN82 COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA

    Oct 1, 2009, 00:00

  • PMC64 DIFFICULTIES WITH THE APPLICATION OF PRO MEASURES TO CULTURES OUTSIDE OF WESTERN EUROPE AND NORTH AMERICA IN MULTI-NATIONAL TRIALS

    Oct 1, 2009, 00:00

  • PCV113 COST-EFFECTIVENESS OF FONDAPARINUX VS ENOXAPARIN IN EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN MAJOR ORTHOPEDIC SURGERY IN POLAND

    Oct 1, 2009, 00:00

  • PMH63 ESTIMATION OF A MULTI-ATTRIBUTE UTILITY FUNCTION FOR THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • VA8 HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED?

    Oct 1, 2009, 00:00

  • PRS33 DEVELOPMENT OF A PREFERENCE-BASED ALGORITHM TO REPORT UTILITIES FOR EXACERBATIONS OF COPD FROM THE EXACT

    Oct 1, 2009, 00:00

  • PCN20 COST-EFFECTIVENESS ASSESSMENT FOR COLOMBIA OF LETROZOLE VS. TAMOXIFEN IN ADJUVANT TREATMENT OF HORMONE RECEPTOR-POSITIVE, POST-MENOPAUSAL EARLY BREAST CANCER WOMEN

    Oct 1, 2009, 00:00

  • PR8 VALIDATION OF THE PROQOL-HIV QUESTIONNAIRE IN LIGHT OF CROSS-CUTURAL DIFFERENCES FROM 5 CONTINENTS

    Oct 1, 2009, 00:00

  • PCV104 THE COST-EFFECTIVENESS ANALYSIS IN SCREENING OF DEEP VEIN THROMBOSIS IN A CLINICAL LABORATORY

    Oct 1, 2009, 00:00

  • PHP53 APPROPRIATE CLASSIFICATION OF HOSPITAL INFUSION SERVICES- MEDICARE REIMBURSEMENT CONSIDERATIONS

    Oct 1, 2009, 00:00

  • PHP22 A SYSTEMATIC REVIEW OF ECONOMIC EVALUATION AND PHARMACOECONOMICS STUDIES IN KOREA

    Oct 1, 2009, 00:00

  • PMS8 ECONOMIC EVALUATION OF THE USE OF HYLAN G-F 20 IN THE HANDLING OF SEVERE KNEE OSTEOARTHROSIS

    Oct 1, 2009, 00:00

  • PCV12 COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCV100 THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE MORTALITY

    Oct 1, 2009, 00:00

  • EE8 BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS- CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME

    Oct 1, 2009, 00:00

  • PMS96 ARE THE ADMINISTRATIVE DATABASE A STRATEGIC TOOL IN DECISION MAKING? CASE STUDY- RHEUMATOID ARTHRITIS IN PIEMONTE REGION

    Oct 1, 2009, 00:00

  • PDB69 SIGNIFICANT REDUCTIONS IN POLYPHARMACY AND HEALTH CARE UTILIZATION WITH INSULIN PUMP THERAPY (CSII) IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • CO1 ESTIMATE AVERAGE MEDICAL COSTS IN THE PRESENCE OF RIGHT-CENSORING

    Oct 1, 2009, 00:00

  • PG18 COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITORS (IV PPI) FOR THE PREVENTION OF GASTRIC OR DUODENAL ULCER REBLEEDING AFTER THERAPEUTIC ENDOSCOPY

    Oct 1, 2009, 00:00

  • PIH26 TREATMENT DURATION AND PRESCRIPTION REFILL RATE FOR VAGINAL ESTROGEN THERAPY IN MEDICAID ENROLLED WOMEN WITH ATROPHIC VAGINITIS

    Oct 1, 2009, 00:00

  • PIH17 ECONOMIC EVALUATION OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO- THE POPULAR HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PRS41 VALIDATION OF THE SPANISH VERSION OF THE 'LIVING WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (LCOPD)' QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PMH33 BURDEN OF BIPOLAR DISORDER- WHAT ARE WE REALLY MEASURING?

    Oct 1, 2009, 00:00

  • PCV166 ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE- A NET COST ANALYSIS REIMBURSEMENT IMPLICATIONS

    Oct 1, 2009, 00:00

  • PCV129 METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE WITH COMMON TREATMENTS

    Oct 1, 2009, 00:00

  • PCN143 WILLINGNESS TO PAY FOR A LIFE-YEAR GAINED FROM THE PERSPECTIVE OF THE GENERAL POPULATION

    Oct 1, 2009, 00:00

  • HP6 EVALUACITICA DE LA LITERATURA

    Oct 1, 2009, 00:00

  • PCV13 COST-EFFECTIVENESS ANALYSIS OF B-TYPE NATRIURETIC PEPTIDE COMPARED TO CLINICAL JUDGMENT IN PATIENTS PRESENTING TO ACUTE CARE SETTINGS WITH DYSPNEA IN UNIFIED HEALTH SYSTEM

    Oct 1, 2009, 00:00

  • PMC13 INDIRECT COST OF ILLNESS IN POLISH ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES

    Oct 1, 2009, 00:00

  • PHP96 ALANYL-GLUTAMINE DIPEPTIDE (DIPEPTIVEN) IN TOTAL PARENTERAL NUTRITION (TPN) THERAPY IN CRITICALLY ILL ITALIAN PATIENTS- A PHARMACOECONOMIC SIMULATION MODEL

    Oct 1, 2009, 00:00

  • CN6 TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

    Oct 1, 2009, 00:00

  • PMS17 BUDGET IMPACT ANALYSIS OF REIMBURSEMENT OF ARAVA (LEFLUNOMIDE) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND

    Oct 1, 2009, 00:00

  • PP2 PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE

    Oct 1, 2009, 00:00

  • PCV5 PERIODONTAL DISEASE, STATIN USE, AND CARDIOVASCULAR EVENTS

    Oct 1, 2009, 00:00

  • PDB6 ADMINISTRATIVE CLAIMS ANALYSIS OF AN L-METHYLFOLATE COMBINATION PRODUCT IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY

    Oct 1, 2009, 00:00

  • PDB73 ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES

    Oct 1, 2009, 00:00

  • PHP69 DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF DRUGS AND MEDICAL SERVICES IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PIN77 THOUGHTS ON THE LABORATORY CULTURES REIMBURSED BY THE SOCIAL SECURITY IN AUSTRIA (OUTPATIENT SECTOR IN PHYSICIANS CARE AND INSTITUTES, BUT NOT HOSPITAL OUTPATIENT CARE)

    Oct 1, 2009, 00:00

  • PHP33 PERCEPTIONS OF THE SAUDI STUDENTS ATTENDING AMERICAN UNIVERSITIES TOWARDS THE NEW SAUDI MANDATORY COOPERATIVE HEALTH INSURANCE PROGRAM (MCHIP) IMPLEMENTED IN SAUDI ARABIA

    Oct 1, 2009, 00:00

  • PHP6 AGRAVOS POR MEDICAMENTOS- FREQUDE

    Oct 1, 2009, 00:00

  • PMS2 SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE- ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING

    Oct 1, 2009, 00:00

  • PMC7 THE NATURE AND SCALE OF INADEQUATE REPORTING OF DICHOTOMOUS OUTCOMES FROM SIX SYSTEMATIC REVIEWS

    Oct 1, 2009, 00:00

  • PHP60 PRICING AND REIMBURSEMENT (PR) IN BRIC COUNTRIES

    Oct 1, 2009, 00:00

  • PRS11 ANALYSIS OF ASTHMA-RELATED OUTCOMES AND COSTS FOR PERSISTENT ASTHMA PATIENTS TREATED WITH BECLOMETHASONE DIPROPIONATE HFA OR BUDESONIDE INHALATION POWDER

    Oct 1, 2009, 00:00

  • PCV16 COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PMS29 HEALTH ECONOMIC COMPARISON OF OUTPATIENT MANAGEMENT OF FIBROMYALGIA BEFORE AND AFTER DIAGNOSIS IN FIVE EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PDB76 ETHICAL ANALYSES IN HEALTH TECHNOLOGY ASSESSMENTS OF DIABETES TREATMENTS

    Oct 1, 2009, 00:00

  • PMH54 COMPLEX ATTENTION-DEFICIT/HYPERACTIVITY DISORDER- PATIENT CHARACTERISTICS, HEALTH CARE UTILIZATION AND COSTS IN A RETROSPECTIVE OBSERVATIONAL CLAIMS STUDY

    Oct 1, 2009, 00:00

  • PCV19 REVISTICA DE ESTUDOS DE CUSTO-EFETIVIDADE DA ROSUVASTATINA VS. ATORVASTATINA

    Oct 1, 2009, 00:00

  • PCN6 COMPARALULAS (NSCLC)- DADOS DO MUNDO REAL

    Oct 1, 2009, 00:00

  • PCV121 ENDOVASCULAR TREATMENT FOR ACUTE ISCHEMIC STROKE IN THE NETHERLANDS. A COST-UTILITY ANALYSIS

    Oct 1, 2009, 00:00

  • PUK9 OPEN COLPOSUSPENSION, TENSION-FREE VAGINAL TAPE AND TENSION-FREE OBTURATOR TAPES IN THE MANAGEMENT OF STRESS URINARY INCONTINENCE IN WOMEN- A COLOMBIAN COST-EFFECTIVENESS MODEL

    Oct 1, 2009, 00:00

  • VA2 A HEALTH ECONOMIC EVALUATION OF A NEW HERPES ZOSTER (HZ) VACCINE FOR THE PREVENTION OF HZ AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM

    Oct 1, 2009, 00:00

  • PCN1 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT- SYSTEMATIC REVIEW AND ...

    Oct 1, 2009, 00:00

  • PSY7 EVALUATION OF MEASURES UNDERTAKEN TO ENHANCE THE ROBUSTNESS OF THE FABRY OUTCOME SURVEY (FOS)

    Oct 1, 2009, 00:00

  • PCN8 COMORBIDITIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER

    Oct 1, 2009, 00:00

  • PCV108 COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE

    Oct 1, 2009, 00:00

  • PHC2 COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS- OF INGUINAL HERNIA REPAIR IN MEXICO

    Oct 1, 2009, 00:00

  • PMH58 TOOL- MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY

    Oct 1, 2009, 00:00

  • PCV14 COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY- ECONOMIC ANALYSIS OF ARBS IN COLOMBIA

    Oct 1, 2009, 00:00

  • MC3 PREDICCIN- PRUEBA DE CONCEPTO

    Oct 1, 2009, 00:00

  • PHP67 THE PROBLEM-BASED LEARNING AS A NEW PRACTICAL METHOD OF SKILL DEVELOPMENT IN THE HEALTH SCIENCES HIGHER EDUCATION

    Oct 1, 2009, 00:00

  • PMH48 COST-EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE VERSUS PAROXETINE AND LITHIUM IN ACUTE BIPOLAR DEPRESSION

    Oct 1, 2009, 00:00

  • PCV151 REVIEW OF STUDIES EVALUATING THE IMPACT OF POLICY-DRIVEN STATIN SWITCH PROGRAMS ON PATIENTS

    Oct 1, 2009, 00:00

  • PCN19 A LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE AND BONE MARROW TRANSPLANTATION (BMT)

    Oct 1, 2009, 00:00

  • PSS29 ADHERENCE TO ANTIGLAUCOMA DRUG TREATMENT IN NEWLY TREATED PATIENTS

    Oct 1, 2009, 00:00

  • PUK16 QUALITY OF LIFE OF ENTERIC-COATED MYCOPHENOLATE SODIUM (EC-MPS) IN RENAL TRANSPLANT RECIPIENTS WITH GASTROINTESTINAL TRACT COMPLAINTS TO MYCOPHENOLATE MOFETIL (MMF). MYVIDA STUDY

    Oct 1, 2009, 00:00

  • CO3 INDIRECT SOCIAL COST OF MULTIPLE SCLEROSIS- RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY

    Oct 1, 2009, 00:00

  • PCN16 EVALUATION OF THE EFFICACY OF THE POPULATION-BASED CERVICAL CANCER SCREENING IN HUNGARY

    Oct 1, 2009, 00:00

  • UT4 DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-LEVEL VERSION OF EQ-5D

    Oct 1, 2009, 00:00

  • PDB42 INSULIN ADMINISTRATION WITH FLEXPEN IS ASSOCIATED WITH INCREASED ADHERENCE AND NO ADDED COSTS TO PAYERS IN A US MANAGED CARE SETTING

    Oct 1, 2009, 00:00

  • PCN104 COST-EFFECTIVENESS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER IN CHINA

    Oct 1, 2009, 00:00

  • PMC19 EVALUATING AN ONLINE INCREMENTAL COST-EFFECTIVENESS CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES

    Oct 1, 2009, 00:00

  • PSY16 THE DIRECT AND INDIRECT COSTS OF THE ANKYLOSING SPONDYLITIS IN THE CZECH REPUBLIC-COMPARISON BETWEEN 2005 AND 2008 STUDIES

    Oct 1, 2009, 00:00

  • PCV56 IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME

    Oct 1, 2009, 00:00

  • PMC49 SENSITIVITY OF 15D, EQ-5D AND SF-6D TO DIABETES COMPLICATIONS- THE CASE OF CORONARY HEART DISEASE

    Oct 1, 2009, 00:00

  • PDB16 GLYCEMIC CONTROL IN THE INPATIENT SETTING- INSULIN ASPART COMPARED TO HUMAN BOLUS INSULIN

    Oct 1, 2009, 00:00

  • PMH50 CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES

    Oct 1, 2009, 00:00

  • PMC46 BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER

    Oct 1, 2009, 00:00

  • PHP20 COST-EFFECTIVE PHARMACEUTICAL CARE IN THE NETHERLANDS? A REVIEW OF THE PHARMACOECONOMICS AND ITS ROLE IN THE ASSESSMENT AND REIMBURSEMENT OF NEW DRUGS

    Oct 1, 2009, 00:00

  • PIN38 COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE

    Oct 1, 2009, 00:00

  • CN2 ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PMS52 COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PATIENT PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PCN105 ECONOMIC EVALUATION OF TRABECTEDIN IN THE TREATMENT OF METASTATIC SOFT-TISSUE SARCOMA (MSTS) IN THE FINNISH SETTING

    Oct 1, 2009, 00:00

  • PMH7 HEALTH CARE RESOURCE UTILIZATION IN THE TREATMENT OF DEPRESSION IN MEXICO

    Oct 1, 2009, 00:00

  • CS6 THE INTRODUCTION OF PRE-ENDOSCOPY (EGD) HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITION (HDIVPPI) IN THE MANAGEMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING (UGIB)-A BUDGET IMPACT ANALYSIS

    Oct 1, 2009, 00:00

  • PSY32 THALIDOMIDE PLUS MELPHALAN AND PREDNISONE FOR AUSTRALIAN PATIENTS NEWLY DIAGNOSED WITH MULTIPLE MYELOMA IS COST-EFFECTIVE WHEN COMPARED WITH MELPHALAN AND PREDNISONE ALONE

    Oct 1, 2009, 00:00

  • PCV6 IMPACTO ECONACA, SOB A PERSPECTIVA DO PAGADOR PRIVADO NO BRASIL

    Oct 1, 2009, 00:00

  • PMC50 MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH EQ-5D

    Oct 1, 2009, 00:00

  • PMH13 TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTIONDEFICIT/ HYPERACTIVITY DISORDER (ADHD)- DATA FROM THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PHP72 A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND

    Oct 1, 2009, 00:00

  • PHP98 COSTS OF BLEEDING RELATED COMPLICATIONS AND BLOOD PRODUCT TRANSFUSIONS AMONG SURGICAL PATIENTS

    Oct 1, 2009, 00:00

  • PCN98 COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY

    Oct 1, 2009, 00:00

  • PSY38 ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA- RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY

    Oct 1, 2009, 00:00

  • PIN68 PSYCHOMETRIC EVALUATION OF THE FUNCTIONAL ASSESSMENT OF HIV INFECTION (FAHl) QUESTIONNAIRE IN TWO CLINICAL PROGRAMMES

    Oct 1, 2009, 00:00

  • PMS59 THE CLINICAL AND ECONOMIC BURDEN OF NONADHERENCE WITH OSTEOPOROSIS MEDICATIONS

    Oct 1, 2009, 00:00

  • PCN7 METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PHP87 COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS

    Oct 1, 2009, 00:00

  • PCN119 COST EFFECTIVENESS ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT THERAPY FOR EARLY STAGE BREAST CANCER BASED ON THE 100-MONTH ANALYSIS OF THE ATAC TRIAL FROM A GERMAN PERSPECTIVE

    Oct 1, 2009, 00:00

  • CASE1 ANDE DO BRASIL

    Oct 1, 2009, 00:00

  • PCN112 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCV21 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS

    Oct 1, 2009, 00:00

  • PMC14 THE COST OF ABSENTEEISM IN POLAND IN 2007-DIFFERENCES WITHIN THE PROVINCES

    Oct 1, 2009, 00:00

  • PCN15 CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN FRANCE- EFFICACY IN REAL LIFE

    Oct 1, 2009, 00:00

  • PHP4 MUDANO A CAMINHO?

    Oct 1, 2009, 00:00

  • PIH43 EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS

    Oct 1, 2009, 00:00

  • PND5 BUDGET IMPACT ANALYSIS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN VARIOUS ITALIAN REGIONS- THE ROLE OF VENLAFAXINE

    Oct 1, 2009, 00:00

  • PMC12 DEVELOPMENT OF COST CATALOGS FOR COST-EFFECTIVENESS ANALYSES IN GERMANY- RESULTS OF A FEASIBILITY STUDY

    Oct 1, 2009, 00:00

  • PSY13 REIMBURSEMENT OF FOODS FOR SPECIAL MEDICAL PURPOSES PRODUCTS FOR PHENYLKETONURIA IN POLAND- A BUDGET IMPACT ANALYSIS

    Oct 1, 2009, 00:00

  • PSY5 IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

    Oct 1, 2009, 00:00

  • PIN66 SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY

    Oct 1, 2009, 00:00

  • PMC2 A STANDARDIZED EVIDENCE BASED APPROACH TO ASSESS NONTRADITIONAL OUTCOME MEASURES FOR USE IN HEALTH CARE DECISION MAKING- THE DIABETES EXAMPLE

    Oct 1, 2009, 00:00

  • PDB1 A COMPARISON OF CLINICAL EFFICACY OF INSULIN GLARGINE ADDED TO ORAL ANTIDIABETIC DRUGS VS PREMIXED INSULINS ALONE IN THE TREATEMENT OF TYPE-2 DIABETES MELLITUS

    Oct 1, 2009, 00:00

  • PMS5 A SYSTEMATIC REVIEW AND MIXED TREATMENT COMPARISON (MTC) OF THE EFFICACY OF PHARMACOLOGICAL TREATMENTS FOR FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PMS6 ESTIMATED CLINICAL ECONOMIC IMPACT OF POOR PATIENT PERSISTENCE WITH OSTEOPOROSIS MEDICATIONS IN BRASIL

    Oct 1, 2009, 00:00

  • PSS18 A FRENCH ECONOMIC MODEL COMPARING COST-EFFECTIVENESS OF DUOTRAV AND XALACOM IN GLAUCOMA

    Oct 1, 2009, 00:00

  • HP1 CONHECIMENTO DA POPULASTICO

    Oct 1, 2009, 00:00

  • PRS3 A COMPARISON OF EFFICACY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1-1 DOSE RATIO IN THE TREATMENT OF BRONCHIAL ASTHMA

    Oct 1, 2009, 00:00

  • PHP55 RECOMMENDATIONS FOR ORPHAN DRUGS IN TWO EU MEMBER STATES-A FOCUS ON THE UNDERLYING PHARMACOECONOMIC EVALUATIONS

    Oct 1, 2009, 00:00

  • PMH31 MEASURING THE ECONOMIC BURDEN OF DEPRESSION USING PATIENT RECORDS

    Oct 1, 2009, 00:00

  • PRS4 INDIRECT COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE AND BUDESONIDE IN THE TREATEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2009, 00:00

  • PMS38 ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN

    Oct 1, 2009, 00:00

  • CS3 UN MODELO DE COSTO-UTILIDAD DEL TRASPLANTE RENAL EN COLOMBIA

    Oct 1, 2009, 00:00

  • PHP64 QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN- A REVIEW OF THE 2003-2009 LITERATURE

    Oct 1, 2009, 00:00

  • PRS13 THE CZECH BURDEN STUDY- SUBGROUP ANALYSIS (BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION)

    Oct 1, 2009, 00:00

  • PCV75 PATIENTS WITH PULMONARY EMBOLISM AFTER ORTHOPAEDIC SURGERY HAVE SIGNIFICANTLY INCREASED COSTS FOR INPATIENT STAY

    Oct 1, 2009, 00:00

  • PND45 PROLONGED-RELEASE MELATONIN- REAL-LIFE EVIDENCE FROM A GERMAN LONGITUDINAL PRESCRIPTION DATABASE

    Oct 1, 2009, 00:00

  • PDB3 FORECASTING THE NUMBER OF DIABETIC PATIENS IN THE UNITED STATES IN 2050

    Oct 1, 2009, 00:00

  • PIH32 WOMENS PREFERENCES FOR OVARIAN STIMULATING HORMONES IN THE TREATMENT OF INFERTILITY

    Oct 1, 2009, 00:00

  • PR1 LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW OF PRO MEASURES FOR BENIGN PROSTATIC HYPERPLASIA

    Oct 1, 2009, 00:00

  • MO2 IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES- A PILOT STUDY

    Oct 1, 2009, 00:00

  • PMS33 COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE ROAD TRAFFIC INJURIES

    Oct 1, 2009, 00:00

  • PSS26 EXPECTED VALUE OF PARTIAL PERFECT INFORMATION IN A MARKOV MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE TYPE PSORIASIS

    Oct 1, 2009, 00:00

  • PIN3 HEPATOCELLULAR CARCINOMA (HCC) RISK ESTIMATION BASED ON CHRONIC HEPATITIS B (CHB) VIRAL LOAD LEVELS IN BRAZILIAN PATIENTS

    Oct 1, 2009, 00:00

  • PHP48 A NEW TEST OF THE CARERQOL INSTRUMENT- MEASURING CARE-RELATED QUALITY OF LIFE' OF INFORMAL CAREGIVERS FOR USE IN ECONOMIC EVALUATIONS

    Oct 1, 2009, 00:00

  • PUK10 COST-EFFECTIVENESS OF COMBINATION THERAPY FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    Oct 1, 2009, 00:00

  • PGI4 ESTUDO FARMAECONO DO OMEPRAZOL EM UTI

    Oct 1, 2009, 00:00

  • PIN16 EVALUACI, D.C

    Oct 1, 2009, 00:00

  • PIN10 COST EFFECTIVENESS OF ENTECAVIR VERSUS LAMIVUDINE IN SUPPRESSING VIRAL REPLICATION TO UNDETECTABLE GOAL IN CHRONIC HEPATITIS B (CHB) PATIENTS IN BRAZIL

    Oct 1, 2009, 00:00

  • PMH41 COST-EFFECTIVENESS ANALYSIS OF ANTI-PSYCHOTICS BY ROUTE IN SCHIZOPHRENIA

    Oct 1, 2009, 00:00

  • PIH29 VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PMC16 QUALITY ASSESSMENT OF PUBLISHED HEALTH ECONOMIC ANALYSES FROM CHINA

    Oct 1, 2009, 00:00

  • PIN80 THE ROLE OF ECONOMIC EVALUATION IN THE HEALTH TECHNOLOGY ASSESSMENT (HTA) OF VACCINES-LESSONS LEARNED FROM FINLAND

    Oct 1, 2009, 00:00

  • PCV12 WHAT IS THE IMPACT OF ARBS VERSUS OTHER ANTI-HYPERTENSIVES ON CV-EVENTS IN HYPERTENSIVE PATIENTS?

    Oct 1, 2009, 00:00

  • PCV124 COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC

    Oct 1, 2009, 00:00

  • PMH18 SCHIZOPHRENIA MODELING- FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE

    Oct 1, 2009, 00:00

  • PCV37 PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS AT MODERATE CARDIOVASCULAR RISK-GREEK RESULTS OF THE PANDORA STUDY

    Oct 1, 2009, 00:00

  • PG12 WORK PRODUCTIVITY IN PRIMARY CARE PATIENTS CONSULTING WITH COMPLAINTS OF UPPER GASTROINTESTINAL SYMPTOMS- ESTIMATES FROM THE DANISH RESPONSE STUDY

    Oct 1, 2009, 00:00

  • PCV50 BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN UK HOSPITALS

    Oct 1, 2009, 00:00

  • PMH9 VALIDATION OF PEER RELATIONS SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER- AN APPLICATION OF RASCH MODELING

    Oct 1, 2009, 00:00

  • PMC32 MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES WITH DIFFERENT SEROTYPES

    Oct 1, 2009, 00:00

  • DB3 USING ELECTRONIC MEDICAL RECORDS TO IDENTIFY UNDIAGNOSED DIABETES MELLITUS IN PRIMARY CARE PRACTICES

    Oct 1, 2009, 00:00

  • CO2 PRESCRIPCIN DE MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES HOSPITALIZADOS

    Oct 1, 2009, 00:00

  • PCN114 COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY- RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION

    Oct 1, 2009, 00:00

  • PRS45 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 475- A POPULATION-BASED STUDY

    Oct 1, 2009, 00:00

  • PIN14 EVALUACIMICO EN UN ENTORNO DE SALUD MUNICIPAL DE CARACAS, VENEZUELA

    Oct 1, 2009, 00:00

  • PHC1 COST-EFFECTIVENESS COMPARISON OF TENSION FREE VERSUS TENSION METHODS- OF INGUINAL HERNIA REPAIR IN BRAZIL

    Oct 1, 2009, 00:00

  • PRS18 COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO FLUTICASONE IN THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA UNDER THE B ...

    Oct 1, 2009, 00:00

  • PDB81 THE ROAD TO INSULIN-A PATH OF TREATMENT ANALYSIS OF REAL-WORLD PHARMACY DATA FROM THE USA

    Oct 1, 2009, 00:00

  • PDB22 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) FOR TYPE 2 DIABETES PATIENTS ON ORAL ANTI-DIABETES DRUGS (OADS)- COST-EFFECTIVENESS IN FRANCE, GERMANY, AND SPAIN

    Oct 1, 2009, 00:00

  • PCN134 VALIDATION OF A KOREAN TRANSLATION OF CANCER THERAPY SATISFACTION QUESTIONNAIRE (CTSQ)- A PILOT STUDY

    Oct 1, 2009, 00:00

  • PRS23 FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC PATIENTS TREATED WITH INHALED CORTICOSTEROIDS, IN REAL LIFE

    Oct 1, 2009, 00:00

  • PDB78 DIFFERENCES IN THE CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES STARTING INSULIN IN THE NORTH, SOUTH AND EAST OF EUROPE- DATA FROM THE CREDIT STUDY

    Oct 1, 2009, 00:00

  • PHP88 HOW DOES THE HEALTH IMPROVEMENT NETWORK (THIN) DATA ON PREVALENCE OF CHRONIC DISEASES COMPARE WITH NATIONAL FIGURES?

    Oct 1, 2009, 00:00

  • PHP47 EARLY ASSESSMENT OF HIGHLY INNOVATIVE MEDICAL TECHNOLOGY- CLINICAL AND ECONOMICAL GAINS OF POINT-OF-CARE APPLICATIONS FOR MEASURING POTASSIUM CONCENTRATIONS

    Oct 1, 2009, 00:00

  • PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND-ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA

    Oct 1, 2009, 00:00

  • PCV79 BURDEN OF ILLNESS STUDY IN PATIENTS WITH RESISTANT HYPERTENSION IN UK

    Oct 1, 2009, 00:00
  • «
  • 141 (current)
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • »